Actinium Pharma to Present Pan-Tumor and AML Data at AACR 2026

The $2.8 billion that Novartis collected from its lutetium-177 drugs in 2025 has set the commercial benchmark every Ac-225 developer is now chasing, and on April 21 in San Diego, Actinium Pharmaceuticals Chairman and CEO Sandesh Seth will make his case that ATNM's platform belongs in that conversation.

Actinium (NYSE American: ATNM) announced April 6 that it will present two preclinical datasets at the American Association for Cancer Research Annual Meeting, running April 17-22 in San Diego. Both posters land on April 21 inside the session "Radiopharmaceutical Platforms for Theranostic Precision Oncology," one covering ATNM-400's potential across solid tumors, the other presenting new mechanistic data on Actimab-A in acute myeloid leukemia.

ATNM-400 is described as a first-in-class Ac-225 radioconjugate targeting a novel antigen distinct from PSMA, the receptor cluster anchoring the most crowded corner of the radiopharmaceutical field. Preclinical activity has already been demonstrated across metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer, including in tumors that resist current targeted therapies. The AACR poster will be the first public disclosure of the expanded pan-tumor dataset.

The Actimab-A presentation addresses a mechanism Actinium calls transcriptional reprogramming, identified as the basis for the drug's mutation-agnostic activity in AML and its ability to enhance response to standard-of-care regimens. AML is genetically heterogeneous enough that mutation-specific therapies address only patient subsets; a mechanism that bypasses mutation status entirely could underpin the Phase 2/3 trial the company is advancing under its existing CRADA with the National Cancer Institute.

For the Ac-225 community, here is what to watch in both sets of slides. On ATNM-400 efficacy, the critical signal is whether tumor regression data holds across all three stated indications or whether one histology is carrying the entire pan-tumor claim. On toxicity, alpha emitters deposit their decay energy over nanometer-scale distances, the source of their therapeutic precision, but that same property creates off-target risk in bone marrow and kidneys. Biodistribution data showing antigen-selective uptake, combined with organ dosimetry within safe thresholds for those tissues, would materially de-risk the program for partners weighing Ac-225 supply commitments. Thin toxicity reporting or efficacy concentrated in a single tumor model are the red flags that will follow the company home from San Diego.

For Actimab-A, the question is whether the transcriptional reprogramming claim is supported by gene expression datasets that actually explain the mutation-agnostic observation, or whether the mechanistic framing is still preliminary. That distinction drives the post-session conversations at AACR that convert to real partnership and academic collaboration interest.

Supply is the binding constraint on how fast any of this translates. Ac-225 producers have scrambled to sign agreements with companies including Bayer, Cellectar Biosciences, and Eckert & Ziegler, but demand from accelerating clinical pipelines continues to outpace new production capacity. Each program that achieves credible efficacy and safety data adds to that demand pressure; each that falls short defers it.

Seth said the AACR presentations "reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities." With approximately 250 patents and patent applications behind the platform and an NCI CRADA already in place for Actimab-A, Actinium brings structural credibility into San Diego. The April 21 session will test whether the preclinical data is ready to match it.